Cargando…
Nanotechnology-Based Approach in Tuberculosis Treatment
Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR c...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292193/ https://www.ncbi.nlm.nih.gov/pubmed/28210505 http://dx.doi.org/10.1155/2017/4920209 |
_version_ | 1782504891292319744 |
---|---|
author | Nasiruddin, Mohammad Neyaz, Md. Kausar Das, Shilpi |
author_facet | Nasiruddin, Mohammad Neyaz, Md. Kausar Das, Shilpi |
author_sort | Nasiruddin, Mohammad |
collection | PubMed |
description | Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB. |
format | Online Article Text |
id | pubmed-5292193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-52921932017-02-16 Nanotechnology-Based Approach in Tuberculosis Treatment Nasiruddin, Mohammad Neyaz, Md. Kausar Das, Shilpi Tuberc Res Treat Review Article Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB. Hindawi Publishing Corporation 2017 2017-01-22 /pmc/articles/PMC5292193/ /pubmed/28210505 http://dx.doi.org/10.1155/2017/4920209 Text en Copyright © 2017 Mohammad Nasiruddin et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Nasiruddin, Mohammad Neyaz, Md. Kausar Das, Shilpi Nanotechnology-Based Approach in Tuberculosis Treatment |
title | Nanotechnology-Based Approach in Tuberculosis Treatment |
title_full | Nanotechnology-Based Approach in Tuberculosis Treatment |
title_fullStr | Nanotechnology-Based Approach in Tuberculosis Treatment |
title_full_unstemmed | Nanotechnology-Based Approach in Tuberculosis Treatment |
title_short | Nanotechnology-Based Approach in Tuberculosis Treatment |
title_sort | nanotechnology-based approach in tuberculosis treatment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292193/ https://www.ncbi.nlm.nih.gov/pubmed/28210505 http://dx.doi.org/10.1155/2017/4920209 |
work_keys_str_mv | AT nasiruddinmohammad nanotechnologybasedapproachintuberculosistreatment AT neyazmdkausar nanotechnologybasedapproachintuberculosistreatment AT dasshilpi nanotechnologybasedapproachintuberculosistreatment |